Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2011, Article ID 601953, 8 pages
http://dx.doi.org/10.1155/2011/601953
Clinical Study

Steroid-Refractory Acute GVHD: Predictors and Outcomes

1Stem Cell Transplantation & Cellular Therapy, M.D. Anderson Cancer Center, Houston, TX 77030, USA
2Blood and Marrow Transplant Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA

Received 19 August 2011; Accepted 30 September 2011

Academic Editor: Myriam Labopin

Copyright © 2011 Jason R. Westin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Couriel, H. Caldera, R. Champlin, and K. Komanduri, “Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management,” Cancer, vol. 101, no. 9, pp. 1936–1946, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. P. J. Martin, G. Schoch, L. Fisher et al., “A retrospective analysis of therapy for acute graft-verus-host disease: initial treatment,” Blood, vol. 76, no. 8, pp. 1464–1472, 1990. View at Google Scholar · View at Scopus
  3. P. J. Martin, C. R. Bachier, H. G. Klingemann et al., “Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement,” Biology of Blood and Marrow Transplantation, vol. 15, no. 7, pp. 777–784, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. S. Arai, J. Margolis, M. Zahurak, V. Anders, and G. B. Vogelsang, “Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment,” Biology of Blood and Marrow Transplantation, vol. 8, no. 3, pp. 155–160, 2002. View at Google Scholar
  5. R. M. Saliba, D. R. Couriel, S. Giralt et al., “Prognostic value of response after upfront therapy for acute GVHD,” Bone Marrow Transplantation. In press. View at Publisher · View at Google Scholar · View at PubMed
  6. J. E. Levine, B. Logan, J. Wu et al., “Graft-versus-host disease treatment: predictors of survival,” Biology of Blood and Marrow Transplantation, vol. 16, no. 12, pp. 1693–1699, 2010. View at Publisher · View at Google Scholar · View at PubMed
  7. M. L. MacMillan, T. E. DeFor, and D. J. Weisdorf, “The best endpoint for acute GVHD treatment trials,” Blood, vol. 115, no. 26, pp. 5412–5417, 2010. View at Publisher · View at Google Scholar · View at PubMed
  8. R. M. Saliba, M. De Lima, S. Giralt et al., “Hyperacute GVHD: risk factors, outcomes, and clinical implications,” Blood, vol. 109, no. 7, pp. 2751–2758, 2007. View at Publisher · View at Google Scholar · View at PubMed
  9. R. Champlin, I. Khouri, A. Shimoni et al., “Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy,” British Journal of Haematology, vol. 111, no. 1, pp. 18–29, 2000. View at Publisher · View at Google Scholar
  10. S. Giralt, K. Ballen, D. Rizzo et al., “Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research,” Biology of Blood and Marrow Transplantation, vol. 15, no. 3, pp. 367–369, 2009. View at Publisher · View at Google Scholar · View at PubMed
  11. D. Przepiorka, D. Weisdorf, P. Martin et al., “Consensus conference on acute GVHD grading,” Bone Marrow Transplantation, vol. 15, no. 6, pp. 825–828, 1995. View at Google Scholar
  12. D. Cox et al., “Regression models and life-tables,” Journal of the Royal Statistical Society Series B, vol. 34, no. 2, pp. 187–220, 1972. View at Google Scholar
  13. R. L. Prentice, J. D. Kalbfleisch, and A. V. Peterson, “The analysis of failure times in the presence of competing risks,” Biometrics, vol. 34, no. 4, pp. 541–554, 1978. View at Google Scholar
  14. S. Paczesny, O. I. Krijanovski, T. M. Braun et al., “A biomarker panel for acute graft-versus-host disease,” Blood, vol. 113, no. 2, pp. 273–278, 2009. View at Publisher · View at Google Scholar · View at PubMed
  15. M. L. MacMillan, D. J. Weisdorf, J. E. Wagner et al., “Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems,” Biology of Blood and Marrow Transplantation, vol. 8, no. 7, pp. 387–394, 2002. View at Google Scholar
  16. D. Weisdorf, R. Haake, B. Blazar et al., “Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome,” Blood, vol. 75, no. 4, pp. 1024–1030, 1990. View at Google Scholar
  17. S. Paczesny, S. W. Choi, and J. L. M. Ferrara, “Acute graft-versus-host disease: new treatment strategies,” Current Opinion in Hematology, vol. 16, no. 6, pp. 427–436, 2009. View at Publisher · View at Google Scholar · View at PubMed